Overview

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital of Nanchang University